Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Colorectal Cancer Rates Declining in Germany

By Drug Discovery Trends Editor | March 14, 2016

The introduction of screening colonoscopy in Germany is showing results: Within ten years of the start of this screening program for the early detection of colorectal cancer, the number of new cases has significantly dropped in the age groups 55 years and over. This is the conclusion drawn by Hermann Brenner, German Cancer Research Center, Heidelberg and co-authors in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2016; 113: 101-6).

Based on data from the German epidemiological cancer registries and the cause-of-death statistics, the researchers reviewed the development of colorectal cancer incidence and mortality rates between 2003 and 2012. During this period, about 20 to 30 percent of eligible persons participated in the screening colonoscopy program. After decades of increase, the age-standardized colorectal cancer incidence declined by 13.8 percent in men and 14.3 percent in women, while the age-standardized colorectal cancer mortality dropped by 20.8 percent in men and 26.5 percent in women. This sharp decline in incidence was selectively observed in the age groups 55 years and over.

Screening colonoscopy from age 55 years was added to the German national statutory cancer screening program in October 2002. Thanks to its ability to detect precursors of colorectal cancer, such as colorectal adenoma, this method has the potential to not only reduce mortality but also the incidence of colorectal cancer.

The authors expect that this downward trend in colorectal cancer incidence and mortality will continue and even accelerate in the years ahead.

Source: Deutches Aerzteblatt International


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE